GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » EV-to-EBIT

AZN (AstraZeneca) EV-to-EBIT : 26.86 (As of Oct. 31, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AstraZeneca's Enterprise Value is $252,520 Mil. AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $9,402 Mil. Therefore, AstraZeneca's EV-to-EBIT for today is 26.86.

The historical rank and industry rank for AstraZeneca's EV-to-EBIT or its related term are showing as below:

AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: -41489.88   Med: 31.02   Max: 246.38
Current: 26.86

During the past 13 years, the highest EV-to-EBIT of AstraZeneca was 246.38. The lowest was -41489.88. And the median was 31.02.

AZN's EV-to-EBIT is ranked worse than
66.67% of 666 companies
in the Drug Manufacturers industry
Industry Median: 17.615 vs AZN: 26.86

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AstraZeneca's Enterprise Value for the quarter that ended in Jun. 2024 was $268,354 Mil. AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $9,402 Mil. AstraZeneca's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 3.50%.


AstraZeneca EV-to-EBIT Historical Data

The historical data trend for AstraZeneca's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca EV-to-EBIT Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.91 27.30 200.99 61.28 27.19

AstraZeneca Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.29 28.38 27.19 25.87 28.54

Competitive Comparison of AstraZeneca's EV-to-EBIT

For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AstraZeneca's EV-to-EBIT falls into.



AstraZeneca EV-to-EBIT Calculation

AstraZeneca's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=252519.699/9402
=26.86

AstraZeneca's current Enterprise Value is $252,520 Mil.
AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,402 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (NAS:AZN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AstraZeneca's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=9402/268354.1146
=3.50 %

AstraZeneca's Enterprise Value for the quarter that ended in Jun. 2024 was $268,354 Mil.
AstraZeneca's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,402 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AstraZeneca's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

From GuruFocus

Q2 2024 AstraZeneca PLC Earnings Presentation Transcript

By GuruFocus Research 07-26-2024